Hbm Holdings Ltd. · HKEX:2142
Hbm — FY2022 Earnings Presentation
34 slides from Hbm's earnings presentation, Mar 29, 2023
Slide 1: 2022 Full Year Results
29 March 2023 2022 Full Year Results Conference Call and webcast for investors and analysts HBM HOLDINGS-B, 02142.HK
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by HBM Holdings Limited (the “Company”) solely for informational purposes and does not constitute an offer to sell or issue or the solicitation of an offer to buy or acquire securities of the Company in any jurisdiction or an inducement to enter into in
Slide 3: Agenda
01 Full Year 2022: A Landmark Year 02 Innovation: Robust Portfolio & Cutting Edge Technology 03 Accelerated Growth: Business Model Expansion 04 Financial Results 05 Outlook: Deliver Value Through Sustainable Growth 3
Slide 4: Full Year 2022: A Landmark Year
Full Year 2022: A Landmark Year Dr. Jingsong Wang Founder, Chairman of the Board and Chief Executive Officer
Slide 5: Harbour BioMed: Next-Generation Global Biotech Company
Harbour BioMed: Next-Generation Global Biotech Company USA Netherlands China 50+ Partners 200+ Projects 14+ Clinical Stage Two pillars driving business since 2022 Leading Next-Gen Immuno-Oncology Therapy Harbour ❑ Global Innovation Listed in 2020 Therapeutics ❑ Worldwide Collaboration Established in
Slide 6: Highly Innovative and Differentiated Global Pipeline
Highly Innovative and Differentiated Global Pipeline Commercial Status Project Target Indication Rights Discovery Pre-Clinical IND Phase I Phase II Phase III BLA Myasthenia Gravis Greater China Rights Ph 3 Completed Batoclimab FcRn HBM9161 Thyroid Eye Disease Out-licensed1 Ph 2/3 Solid Tumors a Mono
Slide 7: New Stage with Numerous Milestones
New Stage with Numerous Milestones Batoclimab (HBM9161): Near commercial stage ✓ Positive outcome for gMG in Ph3 pivotal trial ✓ BLA submission in preparation Harbour Porustobart (HBM4003): Pivotal trial enabling stage Therapeutics ✓ Exciting PoC data in multiple indications ✓ Pivotal-Enabling for n
Slide 8: Transformational Engine for New Growth
Transformational Engine for New Growth Mission Leveraging industry leading technology platforms, Nona Biosciences is committed to provide integrated discovery solution for biotech and pharmaceutical companies from Idea to IND (I to I). Antibody PLUS Leading Technology Integrated Solution Business Mo
Slide 9: Innovation: Robust Portfolio & Cutting Edge Technology
Innovation: Robust Portfolio & Cutting Edge Technology Dr. Yiping Rong Chief Scientific Officer
Slide 10: Porustobart (HBM4003) Next-Gen Anti-CTLA-4 Antibody
Porustobart (HBM4003) Next-Gen Anti-CTLA-4 Antibody with Potential to be the Mainstream of IO Therapeutics MOA1 MOA2 Competitive Advantages Checkpoint Inhibit Treg Depletion 1 Deplete intra-tumoral Treg cells via enhanced ADCC strategy 2 Great safety profile resulted from the reduced drug exposure i
Slide 11: Porustobart (HBM4003) Favorable Safety Profile with Promising Efficacy
Porustobart (HBM4003) Favorable Safety Profile with Promising Efficacy As of August 31, 2022, a total of 173 patients had been treated with Porustobart in clinical studies, including: • 67 patients were treated with Porustobart monotherapy, and • 106 patients were treated with Porustobart in combina
Slide 12: Porustobart (HBM4003) Unprecedented Clinical Benefit in Chinese Melanoma Patients
Porustobart (HBM4003) Unprecedented Clinical Benefit in Chinese Melanoma Patients Robust efficacy observed for HBM4003 + Toripalimab HBM4003 + Toripalimab elicited the highest response rate in Chinese in PD-1 naïve melanoma cohort melanoma patients Best Overall Response by RECIST 1.1, N (%) ORR and
Slide 13: Porustobart (HBM4003) Promising OS Data with Significant Improvement
Porustobart (HBM4003) Promising OS Data with Significant Improvement As of March 6 in combo therapy PD-1 Naïve Melanoma Cohort, - 6-month OS rate was 80% and - median OS data collection in progress OS Rate PD-1 Naïve Cohort 3 month survival rate 0.93 4 month survival rate 0.93 5 month survival rate
Slide 14: Porustobart (HBM4003) Great Opportunities in High-grade Neuroendocrine Neoplasm
Porustobart (HBM4003) Great Opportunities in High-grade Neuroendocrine Neoplasm (NEN) Pathology Categories and Proliferation Activity of NENs Study Design of 4003.6 Poorly differentiated NEC represents a high unmet medical need Cohort 1 HBM4003 0.3mg/kg + Toripalimab 240mg High- • Poorly differentia
Slide 15: HBM1020 (B7H7/HHLA2) Novel B7 Family Immune Escape Mechanism
HBM1020 (B7H7/HHLA2) Novel B7 Family Plays an Alternative Immune Escape Mechanism Beyond PD-L1 Highlights H2L2 ❑ B7H7/HHLA2 is a first-in-class target potentially serving as an alternative immune First and only mAb at escape pathway clinical stage ❑ T cell and NK cell activation activity and excelle
Slide 16: HBM1020 Potential on Various Solid Tumors and Non-overlapping with PD-L1
HBM1020 (B7H7/HHLA2) Potential on Various Solid Tumors and Non-overlapping with PD-L1 Widely Expressed in Various Solid Tumors & Reciprocal to the Expression of PD-L1 Clear cell renal cell Bladder urothelial Pancreatic ductal Colorectal Intrahepatic Gastric cancer Breast cancer Lung cancer carcinoma
Slide 17: HBM7022/AZD5863 Novel 2+1 Format from HBICE Platform
Immune Cell Engager HBM7022/AZD5863 Novel 2+1 Format from HBICE® Platform Validated by MNC Highlights ❑ 2+1 format with better activity and potential larger MOA of HBM7022 therapeutic window ❑ Low CD3 and high CLDN18.2 affinity reduce systemic CLDN18.2 exposure and increase distribution to tumor TCR
Slide 18: HBM7008 (B7H4x4-1BB) First-in-Class Bispecific Antibody
Immune Cell Engager HBM7008 (B7H4x4-1BB) First-in-Class Bispecific Antibody from HBICE® Platform Highlights ❑ Fully human bispecific antibody from the HBICE® platform ❑ Novel immune escape pathway - First-in-class target (B7H4x4-1BB) ❑ Excellent safety profile, potential to avoid 4-1BB liver toxicit
Slide 19: HBICE: Optimized Molecule Generation with Rigorous Scientific Design
HBICE®: Optimized Molecule Generation with Rigorous Scientific Design HBICE® – HCAb-Based Bispecific Platform for Immune Cell Engagers ❑ Rational bispecific molecular design based on specific target Advantages: binding/immune synapse charities Unique and versatile geometric formats & flexibility ❑ S
Slide 20: Building Immune Cell Engager Bispecifics with Cutting Edge Technology
Building Immune Cell Engager Bispecifics with Cutting Edge Technology TAAxNKp30 CD3 based Asymmetric NKp30 HBICE® NK Cell Engager HBM7025 ‘2+1’ HBICE BCMAxCD3 HBM7020 B7H4xCD3 CD3 HBICE® HBM7004 T Cell Engager TAA CLDN18.2xCD3 AZD5863/HBM7022 Immune cell agonist HBICE® targeting B7H4x4-1BB various t
Slide 21: Accelerated Growth: Business Model Expansion
Accelerated Growth: Business Model Expansion Mr. Weihao Xu Chief Financial Officer and Chief Business Officer
Slide 22: Value Creation Through Business Development
Value Creation Through Business Development Cash Received Potential Milestones Royalties 2022 - 2023 Tiered royalties on > $ 80 M ~$2B potential net sales Potential milestones generated Collaborations achieved from collaborations since 2023 from 2022 to 2023 22
Slide 23: Diversified Business Model to Advance Our Portfolio
Harbour Therapeutics: Diversified Business Model to Advance Our Portfolio INTERNAL DEVELOPMET CO-DISCOVERY / CO-DEVELOPMENT ✓Retain strategic value of asset in certain territory/rights and ✓Retain the max value of products provides potential ongoing revenue stream ✓Comprehensive accumulation on expe
Slide 24: Collaboration with Cullinan In 2023
Collaboration with Cullinan In 2023 Co-development on HBM7008 Drives Speed and Delivers both Short/Long Term Values Principal Terms Upfront Payment • $25 million Validation of the assets and company’s Milestone Payment platform • Up to $600 million Integrate the internal and external Royalties resou
Slide 25: Nona's Technology Platforms Have been Endorsed by Renowned Partners
Nona’s Technology Platforms Have been Endorsed by Renowned Partners 25
Slide 26: Financial Results
Financial Results Mr. Weihao Xu Chief Financial Officer and Chief Business Officer
Slide 27: Revenue Significantly Increased in 2022
Revenue Significantly Increased in 2022 Revenue Total revenue significantly increased from US$4.3 million Abundant cash generated from company’s assets and for the year 2021 to US$40.7 million for the year 2023 platform, primarily due to: Upfront payment from : ❑ 40.7 ❑ USD Mil Robust business growt
Slide 28: Committed to R&D for Sustained Business Growth
Committed to R&D for Sustained Business Growth USD Mil Clinical/Pre-clinical trial Research and development costs Employee costs Others 135.1 R&D expenses increased from US$107.1 million for 2021 to US$135.1 million for 2022, was mainly due 107.1 83.6 to increased investments in our key clinical pro
Slide 29: Control on Administrative Expenses to Enhance Operational Efficiency
Control on Administrative Expenses to Enhance Operational Efficiency USD Mil Administrative expenses 40.1 Employee costs Professional expenses Administrative expenses continued to decrease Others (i) a decrease in employee cost from US$28.0 million for the 27.3 year ended 31 December 2021 to US$14.8
Slide 30: Healthy Cash Position to Drive Value Creation
Healthy Cash Position to Drive Value Creation Summary of Consolidated Statements of Financial Position USD Mil 31 December 31 December Cash and bank balances 2022 2021 Cash and bank balances decreased from US$216.3 million to US$171.7 million. Non-current assets 23.1 41.5 USD Mil Current assets 209.
Slide 31: Outlook: Deliver Value through Sustainable Growth
Outlook: Deliver Value through Sustainable Growth Dr. Jingsong Wang Founder, Chairman of the Board and Chief Executive Officer
Slide 32: Harbour BioMed: Strong Growth with Multiple Catalysts in 2023
Harbour BioMed: Strong Growth with Multiple Catalysts in 2023 Harbour Therapeutics Nona Biosciences ❑ HBM9161 Near Commercial Stage ❑ Advance Breakthrough Technology ▪ Positive results of pivotal trial Innovation ▪ BLA submission in 2023 ▪ Antibody PLUS ▪ Next generation therapeutics ❑ HBM4003 Enabl
Slide 33: HARBOUR cae .
HARBOUR cae . BIOMED
Slide 34: Thank You
HARBOUR BIOMED